These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32797801)

  • 1. Comparative Efficacy of the Prokinetic Effects of Cisapride and Tegaserod in Equines.
    Ocampo L; Coello M; Aquino I
    J Equine Vet Sci; 2020 Sep; 92():103179. PubMed ID: 32797801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity.
    Beattie DT; Armstrong SR; Shaw JP; Marquess D; Sandlund C; Smith JA; Taylor JA; Humphrey PP
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jul; 378(1):139-47. PubMed ID: 18408918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart.
    Drici MD; Ebert SN; Wang WX; Rodriguez I; Liu XK; Whitfield BH; Woosley RL
    J Cardiovasc Pharmacol; 1999 Jul; 34(1):82-8. PubMed ID: 10413072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tegaserod (HTF 919) stimulates gut motility in normal horses.
    Lippold BS; Hildebrand J; Straub R
    Equine Vet J; 2004 Nov; 36(7):622-7. PubMed ID: 15581328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and in vitro effects of tegaserod, a serotonin 5-hydroxytryptamine 4 (5-HT4) receptor agonist with prokinetic activity in horses.
    Delco ML; Nieto JE; Craigmill AL; Stanley SD; Snyder JR
    Vet Ther; 2007; 8(1):77-87. PubMed ID: 17447227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An in vitro investigation of the cardiovascular effects of the 5-HT(4) receptor selective agonists, velusetrag and TD-8954.
    Beattie DT; Higgins DL; Ero MP; Amagasu SM; Vickery RG; Kersey K; Hopkins A; Smith JA
    Vascul Pharmacol; 2013 Jan; 58(1-2):150-6. PubMed ID: 23201772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of tegaserod on gut transit in male and female subjects.
    Degen L; Petrig C; Studer D; Schroller S; Beglinger C
    Neurogastroenterol Motil; 2005 Dec; 17(6):821-6. PubMed ID: 16336497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the ether-a-go-go (ERG) potassium channel in smooth muscle of the equine gastrointestinal tract and influence on activity of jejunal smooth muscle.
    Lillich JD; Rakestraw PC; Roussel AJ; Finley MR; Ganta S; Freeman LC
    Am J Vet Res; 2003 Mar; 64(3):267-72. PubMed ID: 12661864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects.
    Degen L; Matzinger D; Merz M; Appel-Dingemanse S; Osborne S; Lüchinger S; Bertold R; Maecke H; Beglinger C
    Aliment Pharmacol Ther; 2001 Nov; 15(11):1745-51. PubMed ID: 11683688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of 5-HT4 receptor-mediated esophageal responses by digital sonomicrometry in the anesthetized rat.
    Armstrong SR; McCullough JL; Beattie DT
    J Pharmacol Toxicol Methods; 2006; 53(3):198-205. PubMed ID: 16168678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inotropic effects of prokinetic agents with 5-HT(4) receptor agonist actions on human isolated myocardial trabeculae.
    Chai W; Chan KY; de Vries R; van den Bogeardt AJ; de Maeyer JH; Schuurkes JA; Villalón CM; Saxena PR; Danser AH; MaassenVanDenBrink A
    Life Sci; 2012 Apr; 90(13-14):538-44. PubMed ID: 22326501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of prokinetic agents, cisapride and metoclopramide, on the bioavailability in humans and intestinal permeability in rats of ranitidine, and intestinal charcoal transit in rats.
    Lee HT; Lee YJ; Chung SJ; Shim CK
    Res Commun Mol Pathol Pharmacol; 2000; 108(5-6):311-23. PubMed ID: 11958284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro effects of 5-hydroxytryptamine and cisapride on the circular smooth muscle of the jejunum of horses.
    Nieto JE; Snyder JR; Kollias-Baker C; Stanley S
    Am J Vet Res; 2000 Dec; 61(12):1561-5. PubMed ID: 11131599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care.
    Layer P; Keller J; Mueller-Lissner S; Rüegg P; Loeffler H
    Digestion; 2005; 71(4):238-44. PubMed ID: 16024929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility.
    Scarpignato C; Pelosini I
    Can J Gastroenterol; 1999 Mar; 13 Suppl A():50A-65A. PubMed ID: 10202210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial.
    Foxx-Orenstein AE; Camilleri M; Szarka LA; McKinzie S; Burton D; Thomforde G; Baxter K; Zinsmeister AR
    Neurogastroenterol Motil; 2007 Oct; 19(10):821-30. PubMed ID: 17539894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of cisapride on the gastrointestinal transit of a solid meal in normal human subjects.
    Edwards CA; Holden S; Brown C; Read NW
    Gut; 1987 Jan; 28(1):13-6. PubMed ID: 3817579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved use of the [13C]octanoic acid breath test as intra-individual parameter to study the effect of a prokinetic drug on gastric emptying in preterm infants with oral feeding intolerance.
    Kulik W; van Weissenbruch MM; Menelik N; Cranendonk A; Kneepkens CM; Lafeber HN
    J Chromatogr B Biomed Sci Appl; 2001 Jan; 750(1):147-53. PubMed ID: 11204215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Actions of the novel gastrointestinal prokinetic agent cisapride on equine bowel motility.
    King JN; Gerring EL
    J Vet Pharmacol Ther; 1988 Dec; 11(4):314-21. PubMed ID: 3210258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased colonic transit in rats produced by a combination of a cholinesterase inhibitor with a 5-HT4 receptor agonist.
    Campbell-Dittmeyer K; Hicks GA; Earnest DL; Greenwood-Van Meerveld B
    Neurogastroenterol Motil; 2009 Nov; 21(11):1197-e108. PubMed ID: 19210632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.